Boehringer Ingelheim Corporate News 
This is an RSS file. You can use it to subscribe to this data in your favourite RSS reader or to display this data on your own website or blog.
This is an RSS file. You can use it to subscribe to this data in your favourite RSS reader or to display this data on your own website or blog.Change in the Board of Managing Directors at Boehringer Ingelheim
(Source: Boehringer Ingelheim Corporate News)
Source: Boehringer Ingelheim Corporate News - August 26, 2019 Category: Research Source Type: news
Social_entrepreneurs_improve_healthcare_access
Social entrepreneurs improve healthcare access across the African continentMaking More Health (MMH) Accelerator program supports social health entrepreneurs to strengthen and scale their workJoint workshop brings together senior executives from Boehringer Ingelheim with promising start-ups from Kenya, Ghana and NigeriaSocial entrepreneurs enter pilot phase in the next six months (Source: Boehringer Ingelheim Corporate News)
Source: Boehringer Ingelheim Corporate News - August 19, 2019 Category: Research Source Type: news
Boehringer Ingelheim opens Health Management Centre in China
The new Health Management Centre integrates animal disease and health diagnostics as well as monitoring toolsThe centre further strengthens the company ’s ability to provide services along the full value chain for Chinese customers and reconfirms its commitment to continuously invest in China (Source: Boehringer Ingelheim Corporate News)
Source: Boehringer Ingelheim Corporate News - August 13, 2019 Category: Research Source Type: news
Boehringer Ingelheim and MD Anderson form collaboration
Boehringer Ingelheim and MD Anderson form unique Virtual Research and Development Center to rapidly advance new cancer therapies New potential gastrointestinal and lung cancer therapies from Boehringer Ingelheim ’s innovative oncology pipeline will be combined with the patient-driven drug-development capabilities at MD Anderson The Center will initially investigate KRAS pathway inhibitors and a TRAILR2 antibody from Boehringer Ingelheim ’s cancer research (Source: Boehringer Ingelheim Corporate News)
Source: Boehringer Ingelheim Corporate News - August 12, 2019 Category: Research Source Type: news
Updated GioTag study data press release
Updated real-world data shows Giotrif ®/Gilotrif® (afatinib) followed by osimertinib provided a median overall survival of up to almost four years in patients with EGFR Del19 and T790M mutation-positive NSCLCSequential afatinib and osimertinib was associated with encouraging time on treatment and overall survival in patients with EGFR T790M-positive NSCLC, especially in patients with Del19 mutationUpdated analysis of the observational GioTag study is published today inFuture Oncology (Source: Boehringer Ingelheim Corporate News)
Source: Boehringer Ingelheim Corporate News - August 2, 2019 Category: Research Source Type: news
thefirsthalf-2019
First half 2019: High levels of investment in R&D and robust organic growthResearch pipeline further strengthenedNet sales growth rise by currency-adjusted 4.6%; human pharmaceuticals growth driversGroup outlook for 2019 confirmed (Source: Boehringer Ingelheim Corporate News)
Source: Boehringer Ingelheim Corporate News - August 1, 2019 Category: Research Source Type: news
INMARK_supports_early_treatment_in_IPF
INMARK ® results suggest prompt treatment of IPF with antifibrotics to slow disease progressionINMARK ® trial results published in The Lancet Respiratory Medicine1Treatment with nintedanib versus placebo for 12 weeks did not affect the rate of change of the biomarker CRPM but was associated with a reduced rate of decline in forced vital capacity (FVC)1Patients with well-preserved lung function showed equivalent amount of decline in FVC to patients with worse baseline lung function in earlier studies1 (Source: Boehringer Ingelheim Corporate News)
Source: Boehringer Ingelheim Corporate News - July 18, 2019 Category: Research Source Type: news
Collaboration with Bridge Biotherapeutics
Boehringer Ingelheim Expands Idiopathic Pulmonary Fibrosis (IPF) Pipeline Through Collaboration and License Agreement with Bridge BiotherapeuticsBoehringer Ingelheim has entered into a collaboration and global license agreement for Bridge Biotherapeutics ’s autotaxin inhibitor BBT-877 to be developed for fibrosing interstitial lung diseases including IPFWith this new partnership Boehringer Ingelheim further expands its commitment to bring new treatments to patients with fibrosing interstitial lung diseases including IPFBridge Biotherapeutics stands to receive up to more than EUR 1.1 billion assuming all milestones are me...
Source: Boehringer Ingelheim Corporate News - July 18, 2019 Category: Research Source Type: news
Acquisition of AMAL Therapeutics
Boehringer Ingelheim Acquires AMAL Therapeutics, Significantly Enriching Its Cancer Immunology Portfolio with Novel Cancer Vaccines Platform Acquisition adds key platform supporting Boehringer Ingelheim ’s focus on patients with difficult-to-treat gastrointestinal and lung cancers AMAL ’s first-in-class proprietary KISIMA® platform leverages peptide/protein-based vaccination technology AMAL will remain at the campus of the University of Geneva in Switzerland and operate as a subsidiary within Boehringer Ingelheim (Source: Boehringer Ingelheim Corporate News)
Source: Boehringer Ingelheim Corporate News - July 15, 2019 Category: Research Source Type: news
Dabigatrans-safety-efficacy-confirmed-in-VTE-children
Dabigatran ’s safety and efficacy established for management of VTE in children First studies to assess treatment and prevention of recurrent venous thromboembolism (VTE) with dabigatran etexilate in children The Phase IIb/III DIVERSITY study demonstrated that the efficacy and safety profile of dabigatran was comparable to standard of care (SOC) for the treatment of children with acute VTE1A second Phase III study reinforced the safety profile in children with persistent VTE risk factors receiving dabigatran for prevention of recurrent VTE2 (Source: Boehringer Ingelheim Corporate News)
Source: Boehringer Ingelheim Corporate News - July 9, 2019 Category: Research Source Type: news
Speech_recognition_can_detect_warning_signals
Speech recognition can detect warning signals for schizophrenia or Alzheimer ' s dementiaBoehringer Ingelheim researchers decode speech patterns with the help of artificial intelligenceSimpler and faster support for the diagnosis of schizophrenia and Alzheimer ’s dementiaObjective: Using language as a biomarker (Source: Boehringer Ingelheim Corporate News)
Source: Boehringer Ingelheim Corporate News - July 8, 2019 Category: Research Source Type: news
FRONTLINE becomes Brand of the Year 2019-2020
FRONTLINE ®becomes ‘Brand of the Year’ 2019-2020 in World Branding AwardsFRONTLINE ® was named global ‘Brand of the Year’ (Animalis Edition) for 2019-2020The Award scores are predominantly constituted by consumer votesWorld Branding Awards recognise and celebrate some of the best global, regional and national brands for their work and achievement (Source: Boehringer Ingelheim Corporate News)
Source: Boehringer Ingelheim Corporate News - July 1, 2019 Category: Research Source Type: news
Collaboration with Yuhan Corporation on NASH
Boehringer Ingelheim Expands Nonalcoholic Steatohepatitis (NASH) R&D Pipeline With New First-in-Class Compound from Yuhan CorporationBoehringer Ingelheim focuses on the development of next generation NASH treatments that target all three key drivers of the disease - steatosis, inflammation and fibrosisCollaboration aims to develop first-in-class dual agonist (GLP1R/FGF21R agonist) for NASHYuhan Corporation to receive up to USD 870 million in upfront and success-based development and commercialization milestones, excluding royalties (Source: Boehringer Ingelheim Corporate News)
Source: Boehringer Ingelheim Corporate News - July 1, 2019 Category: Research Source Type: news
FDA-fast-track-designation-chronic-heart-failure
US FDA grants Fast Track designation to empagliflozin for the treatment of chronic heart failureFast Track designation facilitates the development of new therapies that treat serious conditions and fulfill an unmet medical need. FDA ’s Fast Track designation for empagliflozin underscores the urgent need for new potential treatment options for the 26 million people affected by chronic heart failure worldwide, including 6.5 million in the US.1,2 (Source: Boehringer Ingelheim Corporate News)
Source: Boehringer Ingelheim Corporate News - June 26, 2019 Category: Research Source Type: news
12th Expert Forum on Farm Animal Well-Being
Collaboration key to meeting consumers ’ expectations for better animal welfareThe 12th Expert Forum on Farm Animal Well-Being brought together over 100 industry experts to discuss the latest trends, challenges and opportunities in the industryBy organising such events, Boehringer Ingelheim demonstrates its continuous commitment to and leadership in improving animal welfare (Source: Boehringer Ingelheim Corporate News)
Source: Boehringer Ingelheim Corporate News - June 18, 2019 Category: Research Source Type: news
